About Homeobox protein Hox-A13
Homeobox protein Hox-A13 (HOXA13) is a protein
from Homo sapiens identified by UniProt accession
P31271, 388 residues long.
MolForge cross-references it against 0 known binders and
602 disease associations.
Target properties
| Protein name | Homeobox protein Hox-A13 |
|---|
| UniProt accession | P31271 |
|---|
| Gene | HOXA13 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 388 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (602)
Diseases linked to this target (Open Targets).
- hand-foot-genital syndrome · score 0.81
- Guttmacher syndrome · score 0.61
- diastolic blood pressure · score 0.38
- heel bone mineral density · score 0.38
- systolic blood pressure · score 0.38
- hypertension · score 0.38
- Polydactyly · score 0.37
- Endometrial Endometrioid Adenocarcinoma · score 0.37
- gliomatosis cerebri · score 0.37
- polydactyly · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P31271-F1 | alphafold | PREDICTED | 54.27 | — |
Amino-acid sequence (388 residues)
MTASVLLHPR WIEPTVMFLY DNGGGLVADE LNKNMEGAAA AAAAAAAAAA AGAGGGGFPH PAAAAAGGNF SVAAAAAAAA AAAANQCRNL MAHPAPLAPG AASAYSSAPG EAPPSAAAAA AAAAAAAAAA AAASSSGGPG PAGPAGAEAA KQCSPCSAAA QSSSGPAALP YGYFGSGYYP CARMGPHPNA IKSCAQPASA AAAAAFADKY MDTAGPAAEE FSSRAKEFAF YHQGYAAGPY HHHQPMPGYL DMPVVPGLGG PGESRHEPLG LPMESYQPWA LPNGWNGQMY CPKEQAQPPH LWKSTLPDVV SHPSDASSYR RGRKKRVPYT KVQLKELERE YATNKFITKD KRRRISATTN LSERQVTIWF QNRRVKEKKV INKLKTTS
Explore Homeobox protein Hox-A13 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets